 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Newly Approved Intelence (Etravirine) Dose May Halve Pill BurdenDecember 23, 2010 On December 22, 2010, the Food and Drug Administration approved a new 200 mg Intelence (etravirine) tablet. Intelence was originally approved in 2008, in only a 100 mg tablet formulation. The new 200 mg dosage form can help reduce pill burden for patients taking Intelence. The dosage Dosage and Administration section was changed to state: 200 mg (one 200 mg or two 100 mg tablets) taken twice daily following a meal. Intelence is a Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI), made by Tibotec Therapeutics. The revised product label, reflecting the 200 mg tablet approval can be found at www.accessdata.fda.gov/drugsatfda_docs/label/2010/022187s007lbl.pdf.  This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before adding your comment, please read TheBody.com's Comment Policy.) |
 |
Email
Comments
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Site Policies | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
